<DOC>
	<DOCNO>NCT02597634</DOCNO>
	<brief_summary>This Phase 3 , prospective , randomize , dual-center , double-blind , placebo-controlled , parallel-group study design determine efficacy safety SST-0225 ( 5.4 gram , apply 6 time 24 hour , 48-hour dosing period ) treatment pain associate DOMS .</brief_summary>
	<brief_title>Study SST-0225 Topical Ibuprofen Cream Treatment Delayed Onset Muscle Soreness ( DOMS )</brief_title>
	<detailed_description>This Phase 3 , prospective , randomize , multicenter , double blind , placebo control , parallel group study design determine efficacy safety SST-0225 treatment pain associate DOMS . Healthy volunteer recruit undergo exercise regimen design induce DOMS elbow flexor non-dominant arm . Subjects eligible follow exercise regimen randomize receive treatment SST-0225 placebo 48 hour period . Subjects house clinic first 24 hour dose send home second 24 hour dose period . Arm pain/soreness assess throughout study use 11-point ( 0-10 ) Numeric Rating Scale ( NRS ) . Approximately 150 subject randomize 1:1 ratio SST-0225 placebo three study center US . Subject participation 12 26 day depend length initial screening period . Once subject randomize duration participation 10 day . The expected duration study approximately six month depend enrollment . The sample size may increase maximum 250 base result plan interim analysis describe Section 15.2 protocol .</detailed_description>
	<mesh_term>Myalgia</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Key Inclusion Criteria The following inclusion criterion assess Screening Visit time randomization : 1 . Men woman age 1665 , inclusive 2 . Subjects must able read , understand , sign , date inform consent/assent document indicating ( legally acceptable representative ) inform pertinent aspect trial 3 . Female subject must agree use medically acceptable contraceptive method Screening Visit ( unless otherwise state ) end study ( EOS ) . 4 . Subjects must able speak , read , comprehend English Spanish , complete require measurement outline protocol 5 . Subjects must agree refrain upper body resistance train unusual excessive exercise screen period duration study , include followup 6 . Subjects must agree refrain use restrict therapy screen period completion dose period Key Exclusion Criteria The following exclusion criterion assess Screening Visit time randomization . 1 . Subjects injury nondominant arm adhesive capsulitis , bursitis , rotator cuff syndrome , within six month prior Screening Visit 2 . Subjects medial lateral epicondylitis ( tennis elbow ) nondominant arm 3 . Subjects open wound , skin irritation , infection nondominant arm area treat 4 . Subjects engage upper body resistance train six month prior Screening Visit 5 . Subjects actively engage manual physical labor job ( i.e . brick layer , construction worker , carpenter , house painter ) 6 . Subjects participate strenuous exercise medical reason 7 . Subjects abnormal laboratory parameter Screening Visit , opinion Investigator , could confound interpretation study result 8 . Subjects abnormal physical exam , opinion Investigator , would interfere study participation 9 . Subjects receive oral injectable systemic corticosteroid within three month prior Screening Visit 10 . Subjects osteoarthritis hand , finger , elbow , shoulder 11 . Subjects chronic pain 12 . Subjects allergy history allergy intolerance aspirin , NSAIDs , acetaminophen excipients IP ( Larginine hydrochloride , glyceryl stearate , cetyl alcohol , squalane , xanthan gum , isopropyl myristate , oleic acid , propylene glycol , polysorbate 20 , methyl paraben , phenoxyethanol , propyl paraben , dimethicone ) 13 . Subjects current viral bacterial infection 14 . Subjects certain medical condition , include : 1 . Peptic ulcer disease 2 . Fibromyalgia 3 . Clinically important gastrointestinal , renal , hepatic disease within past six month , opinion Investigator 4 . Clinically significant cardiovascular disease , opinion Investigator , stable past six month 5 . Uncontrolled hypertension indicate systolic blood pressure ≥ 160 mmHg diastolic blood pressure ≥ 100 mmHg 6 . Coagulation disorder hematologic disease 7 . History seizures 8 . Known , significant , preexisting condition opinion Investigator would affect interpretation study data . 15 . Subjects certain myopathy metabolic defect , include : 1 . Polymyositis ( inflammatory ) 2 . Sickle cell trait ( genetic ) 3 . Lipid metabolism disorder ( carnitine deficiency , carnitine palmitoyl transferase [ CPT ] deficiency , βoxidation enzyme defect ) 4 . Glucose metabolism disorder ( phosphorylase deficiency [ McArdle 's Disease ] , glycolysis enzyme defect ) . 16 . Subjects take anticoagulant , angiotensinconverting enzyme inhibitor , lithium methotrexate within 30 day prior Screening Visit 17 . Subjects currently take tricyclic antidepressant include , limited following : 1. amitriptyline 2. clomipramine ( Anafranil™ ) 3. doxepin ( Sinequan® ) 4. imipramine ( Tofranil™ ) 5. trimipramine ( Surmontil® ) 6. amoxapine ( Amoxapine Tablets ) 7. desipramine ( Norpramin® ) 8. nortriptyline ( Pamelor™ ) 9. protriptyline ( Vivactil® ) 18 . Subjects know alcohol abuse , drug dependency , history significant psychiatric illness within past 12 month prior Screening Visit 19 . Subjects use investigational drug within 30 day prior Screening Visit 20 . Subjects take diuretic , statin , cyclosporine , colchicine 21 . Subjects positive drug screen 22 . Females pregnant lactate 23 . Subjects colorblind</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>